Michael Feld Sells 74 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 74 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $196.08, for a total transaction of $14,509.92. Following the transaction, the executive vice president owned 16,506 shares in the company, valued at $3,236,496.48. The trade was a 0.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Michael Feld also recently made the following trade(s):

• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $193.36, for a total transaction of $14,502.00.
• On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $186.01, for a total value of $10,602.57.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $195.69 on Wednesday. The business has a fifty day moving average of $190.58 and a 200 day moving average of $186.68. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The firm has a market capitalization of $55.76 billion, a price-to-earnings ratio of 33.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a $1.05 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent research reports. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Four investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $205.64.

Hedge Funds Weigh In On Becton, Dickinson and Company

Large investors have recently bought and sold shares of the business. Bill Few Associates Inc. increased its position in shares of Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 55 shares in the last quarter. Gilbert & Cook Inc. grew its stake in Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after acquiring an additional 56 shares during the period. Mendel Money Management increased its holdings in Becton, Dickinson and Company by 2.6% in the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after acquiring an additional 58 shares in the last quarter. Focus Financial Network Inc. raised its position in Becton, Dickinson and Company by 2.2% during the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after acquiring an additional 58 shares during the period. Finally, Phillips Wealth Planners LLC raised its position in Becton, Dickinson and Company by 2.7% during the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after acquiring an additional 58 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.